4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP)

被引:46
作者
Banoglu, Erden [1 ]
Celikoglu, Ersan [1 ]
Voelker, Susanna [2 ]
Olgac, Abdurrahman [1 ]
Gerstmeier, Jana [2 ]
Garscha, Ulrike [2 ]
Caliskan, Burcu [1 ]
Schubert, Ulrich S. [3 ,4 ]
Carotti, Andrea [5 ]
Macchiarulo, Antonio [5 ]
Werz, Oliver [2 ,3 ]
机构
[1] Gazi Univ, Dept Pharmaceut Chem, Fac Pharm, TR-06330 Ankara, Turkey
[2] Univ Jena, Inst Pharm, Chair Pharmaceut Med Chem, Philosophenweg 14, D-07743 Jena, Germany
[3] Univ Jena, JCSM, Philosophenweg 7, D-07743 Jena, Germany
[4] Univ Jena, Lab Organ & Macromol Chem IOMC, Humboldtstr 10, D-07743 Jena, Germany
[5] Univ Perugia, Dipartimento Sci Farmaceut, Via Liceo 1, I-06123 Perugia, Italy
关键词
Inflammation; Leukotrienes; 5-lipoxygenase; 5-lipoxygenase-activating protein; Isoxazole; INFLAMMATORY DISEASES; MYELOID-LEUKEMIA; ATHEROSCLEROSIS; ASTHMA; CANCER; DISCOVERY; DESIGN; CELLS; TOLERABILITY; NEUTROPHILS;
D O I
10.1016/j.ejmech.2016.02.027
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this article, we report novel leukotriene (LT) biosynthesis inhibitors that may target 5-lipoxygenase-activating protein (FLAP) based on the previously identified isoxazole derivative (8). The design and synthesis was directed towards a subset of 4,5-diaryl-isoxazole-3-carboxylic acid derivatives as LT biosynthesis inhibitors. Biological evaluation disclosed a new skeleton of potential anti-inflammatory agents, exemplified by 39 and 40, which potently inhibit cellular 5-LO product synthesis (IC50 = 0.24 mu M, each) seemingly by targeting FLAP with weak inhibition on 5-LO (IC50 > 8 mu M). Docking studies and molecular dynamic simulations with 5-LO and FLAP provide valuable insights into potential binding modes of the inhibitors. Together, these diaryl-isoxazol-3-carboxylic acids may possess potential as leads for development of effective anti-inflammatory drugs through inhibition of LT biosynthesis. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 47 条
[41]   The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma [J].
Wasfi, Yasmine S. ;
Villaran, Cesar ;
de Tilleghem, Celine Le Bailly ;
Smugar, Steven S. ;
Hanley, William D. ;
Reiss, Theodore F. ;
Knorr, Barbara A. .
RESPIRATORY MEDICINE, 2012, 106 (01) :34-46
[42]   Zileuton: The first 5-lipoxygenase inhibitor for the treatment of asthma [J].
Wenzel, SE ;
Kamada, AK .
ANNALS OF PHARMACOTHERAPY, 1996, 30 (7-8) :858-864
[43]   Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes [J].
Werz, O ;
Bürkert, E ;
Samuelsson, B ;
Rådmark, O ;
Steinhilber, D .
BLOOD, 2002, 99 (03) :1044-1052
[44]   Therapeutic options for 5-lipoxygenase inhibitors [J].
Werz, Oliver ;
Steinhilber, Dieter .
PHARMACOLOGY & THERAPEUTICS, 2006, 112 (03) :701-718
[45]  
Werz Oliver, 2002, Current Drug Targets - Inflammation and Allergy, V1, P23, DOI 10.2174/1568010023344959
[46]   The potential link between atherosclerosis and the 5-lipoxygenase pathway:: investigational agents with new implications for the cardiovascular field [J].
Whatling, Carl ;
McPheat, William ;
Herslof, Margareta .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (12) :1879-1893
[47]  
Xu SS, 2013, CLIN INVEST MED, V36, pE282